Sri Lankan pharmaceutical manufacturers have explored new export markets, business partnerships and technology collaborations at CPHI Worldwide 2026, a major international pharmaceutical industry exhibition held in Milan, Italy.
The Sri Lanka Export Development Board (EDB), in collaboration with the Embassy of Sri Lanka in Rome and the Consulate General of Sri Lanka in Milan, facilitated an exposure visit for a five-member business delegation representing five local companies.
The 37th edition of CPHI Worldwide took place from October 6 to 8 at Fiera Milano, providing Sri Lankan manufacturers with opportunities to connect with international industry stakeholders and explore avenues to expand their global market presence.
The participating companies were the State Pharmaceutical Manufacturing Corporation, Siddhalepa Exports (Pvt) Ltd, Lina Manufacturing (Pvt) Ltd, Vetpharma Biotechnology (Pvt) Ltd and Aithra Pharmaceuticals (Pvt) Ltd. The delegation represented a range of sectors, including pharmaceuticals, veterinary products, cosmeceuticals and natural products.
CPHI Worldwide brings together pharmaceutical manufacturers, active pharmaceutical ingredient suppliers, contract development and manufacturing organisations, packaging providers and specialised technical service companies from across the global pharmaceutical supply chain.
During the exhibition, the Sri Lankan delegation engaged with international organisations, including Barbados Pharmaceutical Inc., Orion GXP Consulting, Gruppo Farmalpresa, Intertek, Nanopharm and NATAC, as well as representatives from Tanzania’s Ministry of Health.
Discussions focused on potential business partnerships, technical cooperation, pharmaceutical product development, natural ingredients, regulatory requirements and strategies for international market development.
The Consulate General of Sri Lanka in Milan also organised dedicated business networking sessions, enabling delegates to establish connections with prospective buyers, distributors and other industry representatives.
The participation comes as Sri Lankan pharmaceutical manufacturers continue to navigate the challenges of meeting increasingly stringent international regulatory requirements, including European Union Good Manufacturing Practice (EU-GMP) standards. Obtaining market authorisation in highly regulated markets can be a lengthy and costly process, making international collaboration and industry exposure important for companies seeking to expand their export operations.
Through its participation at CPHI Worldwide 2026, the Sri Lankan delegation sought to strengthen international industry connections and identify opportunities to improve competitiveness, develop technical capabilities and expand the global reach of locally manufactured pharmaceutical and related products.